GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (FRA:NV4) » Definitions » Shiller PE Ratio

Cellectar Biosciences (FRA:NV4) Shiller PE Ratio : (As of May. 21, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cellectar Biosciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cellectar Biosciences Shiller PE Ratio Historical Data

The historical data trend for Cellectar Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Shiller PE Ratio Chart

Cellectar Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cellectar Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cellectar Biosciences's Shiller PE Ratio

For the Biotechnology subindustry, Cellectar Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectar Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's Shiller PE Ratio falls into.



Cellectar Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cellectar Biosciences's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Cellectar Biosciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.681/131.7762*131.7762
=-0.681

Current CPI (Mar. 2024) = 131.7762.

Cellectar Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -537.280 100.560 -704.068
201409 46.560 100.428 61.094
201412 -358.941 99.070 -477.440
201503 -280.896 99.621 -371.562
201506 -269.082 100.684 -352.177
201509 -219.186 100.392 -287.709
201512 137.700 99.792 181.833
201603 81.718 100.470 107.181
201606 -43.610 101.688 -56.514
201609 -38.313 101.861 -49.565
201612 -52.712 101.863 -68.192
201703 -22.440 102.862 -28.748
201706 -20.648 103.349 -26.327
201709 -21.646 104.136 -27.391
201712 -28.730 104.011 -36.399
201803 -16.788 105.290 -21.011
201806 -14.466 106.317 -17.930
201809 -14.141 106.507 -17.496
201812 -7.109 105.998 -8.838
201903 -6.726 107.251 -8.264
201906 -4.071 108.070 -4.964
201909 -3.814 108.329 -4.640
201912 -2.970 108.420 -3.610
202003 -3.801 108.902 -4.599
202006 -2.309 108.767 -2.797
202009 -1.274 109.815 -1.529
202012 -0.575 109.897 -0.689
202103 -1.092 111.754 -1.288
202106 -0.946 114.631 -1.087
202109 -0.825 115.734 -0.939
202112 -0.850 117.630 -0.952
202203 -0.908 121.301 -0.986
202206 -1.154 125.017 -1.216
202209 -1.293 125.227 -1.361
202212 -0.519 125.222 -0.546
202303 -0.710 127.348 -0.735
202306 -0.674 128.729 -0.690
202309 -1.134 129.860 -1.151
202312 -0.367 129.419 -0.374
202403 -0.681 131.776 -0.681

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cellectar Biosciences  (FRA:NV4) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cellectar Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectar Biosciences (FRA:NV4) Business Description

Traded in Other Exchanges
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Cellectar Biosciences (FRA:NV4) Headlines

No Headlines